Stryker Corporation
NYSE•SYK
CEO: Mr. Kevin A. Lobo
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1980-03-17
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Contact Information
Market Cap
$119.69B
P/E (TTM)
35.8
27.7
Dividend Yield
1.1%
52W High
$404.87
52W Low
$281.00
52W Range
Rank25Top 11.9%
5.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$6.02B+0.00%
4-Quarter Trend
EPS
$1.95+0.00%
4-Quarter Trend
FCF
$415.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Strong Net Sales Growth Reported net sales reached $25.12B, growing 11.2% compared to 2024; constant currency growth was 10.7%.
Earnings Per Share Rises Diluted EPS was $8.40, reflecting 8.2% growth; Adjusted diluted EPS grew 11.8% to $13.63.
Segment Performance Divergence MedSurg/Neurotechnology sales grew 15.7% reported, while Orthopaedics sales increased 4.3% reported in 2025.
Aggressive Capital Deployment Invested $4.96B in acquisitions, including Inari; paid $1.28B in dividends during the fiscal year.
Risk Factors
Supply Chain Volatility Risks Reliance on sole-source suppliers for materials risks product shortages and increased operating costs due to inflation or tariffs.
Regulatory Burden Increases Extensive FDA and EU MDR regulations require compliance costs and could lead to sanctions, recalls, or sales restrictions.
Intellectual Property Litigation Ongoing IP infringement claims are expensive to defend and could prevent selling key products or result in damage payments.
Cybersecurity Threat Landscape Extensive reliance on IT systems faces evolving, sophisticated cyber threats, risking data integrity and operational continuity.
Outlook
Mako Robotics Expansion Continued global Mako SmartRobotics footprint expansion; Mako 4 platform launched for Total Hip Advanced Primary/Revision procedures.
New Product Launches Launched OptaBlate BVN for vertebrogenic pain; Mako Shoulder commercial launch planned for Q1 2026.
Capital Structure Management Refinanced debt facilities in February 2025, increasing revolving credit capacity to $3.00B maturing in 2030.
Managing Tax Uncertainty Evaluating impact of global tax reform, including OECD Pillar 2 framework, on future effective tax rate calculations.
Peer Comparison
Revenue (TTM)
$407.91B
$403.43B
$76.39B
Gross Margin (Latest Quarter)
86.8%
79.2%
75.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AMGN | $191.70B | 24.6 | 89.4% | 62.0% |
| GILD | $155.93B | 16.9 | 42.2% | 39.4% |
| PFE | $149.38B | 19.9 | 8.4% | 31.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.0%
Flat Growth
4Q Net Income CAGR
-5.5%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Jul 30, 2026
EPS:$3.49
|Revenue:$6.58B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data